BMS 986141

Drug Profile

BMS 986141

Alternative Names: BMS-986141; UDM-003183

Latest Information Update: 26 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb; Institute for Research in Immunology and Cancer - Commercialization of Research
  • Class Antithrombotics; Small molecules
  • Mechanism of Action PAR-4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis

Most Recent Events

  • 16 May 2018 Bristol-Myers Squibb terminates a phase II trial in Thrombosis in Spain, USA and Japan (PO) (NCT02671461)
  • 21 Mar 2018 Bristol-Myers Squibb withdrew a phase I bioavailability trial prior to enrolment as the business objectives have changed in Healthy volunteers in USA (PO) (NCT03035734)
  • 11 Nov 2017 Pharmacodynamics data from a preclinical trial in Thrombosis presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top